Bone surgery has always walked a fine line. One wrong move with a traditional drill, and nearby nerves or blood vessels could suffer serious damage. These complications aren’t rare either—they contribute to over €4 billion in global healthcare costs every year.
Surgify Medical wants to end that risk. The Finnish medtech startup just raised €7 million in Series A funding to expand its soft tissue-protective drill, the Surgify Halo, across the EU and the U.S.
ZEISS Ventures led the round, joined by the European Innovation Council (EIC) Fund, Lednil, and Cascara Ventures. This brings Surgify’s total funding to €14 million.
The startup already achieved major wins on the regulatory front. In late 2023, the U.S. FDA cleared Surgify’s first device. Then in March 2025, more models earned approval—paving the way for U.S. market expansion.
Surgical Safety with Halo™: Real Results in the OR
The Surgify Halo drill uses smart, pressure-sensitive technology to tell the difference between bone and soft tissue. When it hits bone, the protective ring retracts to allow drilling. But the moment it contacts soft tissue, the ring extends to shield the cutting edges.
This real-time protection helps surgeons avoid costly errors. In pre-clinical studies across 77 surgeries, zero soft tissue injuries occurred when using the Halo system—compared to a 29% injury rate with traditional tools. A later clinical study with 20 neurosurgery patients confirmed the same result: not a single injury.
Hospitals are taking note. Helsinki University Hospital first tested Halo in 2021. Since then, over 1,000 surgeries across the EU and U.S. have used the tool successfully. Surgeons in Germany recently reported high stability and precision when using it during spine operations.
Hospitals also stand to save big. By preventing soft tissue damage, Surgify’s system can help cut costs by as much as €3 million annually.
An Award-Winning Team and Vision
Surgify Medical was founded in 2017 by a team from Aalto University. CEO Dr. Visa Sippola previously conducted neurosurgery research. CTO Shahab Haeri is a mechanical engineer. Chief Regulatory Officer Jukka Kreander specializes in health informatics. Together, they blend medical expertise with deep tech innovation.
In 2024, Surgify earned a Red Dot Award for Product Design. They also launched a smaller 4.0 mm version of the Halo drill—perfect for tight spaces in spine, ENT, and brain procedures.
The company continues to validate its tech through ongoing clinical research. A current randomized study is evaluating Halo in revision spine surgeries, with 30 patients expected to participate.
From its base in Espoo, Finland, Surgify is scaling fast. It now operates in Sweden, Denmark, and the U.S., where adoption is accelerating. With the U.S. small bone and joint market valued at $2.6 billion and rising, Surgify is entering at the right time.
ZEISS Ventures sees the potential. Dr. Boris Hofmann praised Halo for combining speed with surgical control, calling it a game-changer. Chairman Alan Raffensperger added that Halo is already impacting robotic-assisted procedures.
Dr. Sippola summed it up: “With funding, FDA clearance, and growing hospital use, we’re ready to bring Halo to more surgeons—and protect more patients—worldwide.”
